Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Technology Strategies - Will They Pay Off?
  • The Industrialization of Drug Discovery
  • Biologics Platforms
  • Enlight Biosciences: Big Pharma' s Technology Collaboration
• Organizational Structures and Strategies
  • GlaxoSmithKline
  • Novartis
  • Pfi zer
  • Sanofi -Aventis
• Building R&D Through Business Development
• Pharma-Pharma Partnering
  • AstraZeneca and Merck: Early-Stage Development for Cancer
  • GlaxoSmithKline and Pfi zer: A Joint Venture for HIV
• Moving R&D to China and India
• Outlook for Pharmaceutical R&D

Tables

• 1. Top-Selling Biologic Drugs
• 2. Bristol-Myers Squibb' s “String of Pearls” Deals
• 3. GlaxoSmithKline/Pfi zer HIV Joint Venture Portfolio

Figures

• 1. Combined R&D Expense vs. New Molecular Entity Approvals for 15 Top Pharmaceutical Companies, 2000-2008
• 2. Business Model for Enlight Biosciences
• 3. Simplifi ed Scheme of the Mechanisms of Action of MK-2206 and AZD-6244